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Developmental epileptic encephalopathies are devastating disorders characterized by
intractable epileptic seizures and developmental delay. Here, we report an allelic series of
germline recessive mutations in UGDH in 36 cases from 25 families presenting with epileptic
encephalopathy with developmental delay and hypotonia. UGDH encodes an oxidoreductase
that converts UDP-glucose to UDP-glucuronic acid, a key component of speciﬁc proteoglycans and glycolipids. Consistent with being loss-of-function alleles, we show using patients’
primary ﬁbroblasts and biochemical assays, that these mutations either impair UGDH stability, oligomerization, or enzymatic activity. In vitro, patient-derived cerebral organoids are
smaller with a reduced number of proliferating neuronal progenitors while mutant ugdh
zebraﬁsh do not phenocopy the human disease. Our study deﬁnes UGDH as a key player for
the production of extracellular matrix components that are essential for human brain
development. Based on the incidence of variants observed, UGDH mutations are likely to be a
frequent cause of recessive epileptic encephalopathy.
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D

evelopmental epileptic encephalopathies are a clinically
and genetically heterogeneous group of devastating disorders characterized by severe epileptic seizures that are
accompanied by developmental delay or regression1. In several
cases, a genetic etiology has been identiﬁed2. Germline mutations
in these genes lead to different pathophysiological defects2,
including ion channel dysfunction, synaptic impairment, transporter defects and metabolic abnormalities, such as deﬁciencies in
glycosylation pathways3–5. However, the genetic cause of many
epileptic encephalopathies remains unknown.
Defects of glycosylation are causing more than 100 rare human
genetic disorders, most of these affecting the central and/or
peripheral nervous systems. Patients typically show developmental delay or intellectual disability, seizures, neuropathy, and
metabolic abnormalities in multiple organ systems3. Adding the
correct sugar chains (glycans) to proteins and lipids signiﬁcantly
impacts their function. UGDH (MIM603370) codes for an
enzyme that converts UDP-glucose (UDP-Glc) to UDPglucuronic acid (UDP-GlcA) through the concomitant reduction of NAD+ into NADH6,7. UDP-GlcA is not only needed for
detoxiﬁcation via glucuronidation, but is also an obligate precursor for the synthesis of glycosaminoglycans (GAGs), and
therefore an important component of proteoglycans of the
extracellular matrix.
In this study, we establish UGDH as a gene responsible for
autosomal recessive developmental epileptic encephalopathy in
humans. We catalog a series of 30 patients from 25 families with
biallelic germline UGDH variants. Using patients’ primary
ﬁbroblasts and biochemical assays, we demonstrate that these are
loss-of-function alleles. While mutant ugdh zebraﬁsh did not
phenocopy the disease, we bring evidence that patient-derived
cerebral organoids, which were smaller due to a reduced number
of proliferating neuronal progenitors, can serve as an alternative
disease-in-a-dish model for in vitro functional studies.
Results
Biallelic mutations in UGDH cause developmental epileptic
encephalopathy. To identify the genetic cause of a developmental
epileptic encephalopathy in a consanguineous Palestinian family
with three affected siblings (Fig. 1a, F1), we performed exome
sequencing on two affected siblings. No mutations in genes
known to be associated with neurological disorders (either
recessive or dominant) were found. As the consanguineous
background and the pedigree suggested autosomal recessive
inheritance, we focused on homozygous or compound heterozygous variants shared by the affected siblings. A rare homozygous variant c.131C > T in UDP-Glucose 6-Dehydrogenase
(UGDH), which changes alanine into valine at position 44 of the
UGDH protein, was the only segregating candidate variant. The
UGDH p.A44V missense affects a highly conserved residue
(Suppl. Fig. 1b and phyloP 100-way8 score 9.43), is extremely rare
in public databases (not present in EVS65009, MAF of 0.0017% in
ExAC10) and is a good candidate according to in silico prediction
scores (CADD score11 of 33) (Suppl. Table 1). We then (i)
screened the GENESIS12 database for additional patients with
recessive UGDH variants, (ii) contacted the EuroEPINOMICS
RES Consortium, and (iii) searched with the help of GeneMatcher13 for additional families with germline UGDH mutations. We uncovered 27 additional patients from 24 families
carrying either compound heterozygous or homozygous UGDH
variants (Fig. 1a and Suppl. Fig. 1a). All variants were absent or
had an extremely low frequency (<0.01%) in the public databases
ExAC/gnomAD10 and EVS6500 (Suppl. Table 2). Nineteen of the
20 identiﬁed missense variants are in highly conserved residues
(Suppl. Fig. 1b and phyloP 100-way between 3.81 and 9.43). The
2

A44V variant, identiﬁed in the Palestinian index family, was also
found in two additional families from Puerto Rico (F11) and from
Spain (F13) indicative of independent but recurrent mutation in
this residue. In ExAC the A44V variant is observed in African
(MAF 0.0096%) and European (Non-Finish) populations (MAF
0.0015%), however, it is not present in the Greater Middle East
Variome.
All 30 patients carrying biallelic mutations in UGDH presented
with a common core phenotype consisting of marked developmental delay, epilepsy, mild dysmorphism, and motor disorder
with axial hypotonia (Table 1 and Suppl. Data 1). Dysmorphic
facial features such as short and ﬂattened philtrum, outward
protruding earlobes, ptosis, or blepharophimosis were mild but
frequently present (Fig. 1b and Suppl. Data 1). Most patients have
severe epilepsy ranging from neonatal onset developmental
epileptic encephalopathy to infantile developmental epileptic
encephalopathy (27 patients, 90%), of which 16 (53%) had
infantile spasms (Table 1). Three patients have developmental
encephalopathy, of which two had seizures in the setting of fever
(F5-II:1 and F5-II:2). Only these two patients were seizure-free on
sodium valproate. All other patients, except for one patient who
seemed to beneﬁt from ketogenic diet, did not respond to
antiepileptic treatment. All patients had a severe motor disorder
with axial hypotonia, while some patients presented with limb
spasticity (43%), dystonia (17%), ataxia, chorea, and tremor,
which were often present prior to onset of seizures. Twenty-four
out of the 30 (80%) were noted to have swallowing difﬁculties and
gastrostomy tubes were required for feeding in 12 infants. None
but two patients (F5-II:1 and II:2) achieved sitting ability. A
moderate to severe intellectual disability was observed in all
patients. Three patients were deceased between 4 months and 6
years of age (Table 1 and Suppl. Data 1). Electroencephalography
(EEG) was markedly abnormal with a burst suppression pattern
in the neonatal period, hypsarrhythmia in affected children with
infantile spasms, and focal and/or generalized spike-wave
complexes in childhood (Suppl. Data 1). MRI revealed a spectrum
of abnormalities with delayed myelination and enlarged ventricles
probably due to cerebral and cerebellar atrophy in more severely
affected patients without any signs of maldevelopment (Fig. 1c
and Suppl. Data 1).
UGDH mutations behave as hypomorphic alleles. The UGDH
oxidoreductase consists of three distinct domains14: the NADbinding (N-terminal) and UDP-binding (C-terminal) domains,
and an internal domain that bridges the two termini together14.
The UGDH enzyme assembles into a disc-shaped double layer
composed of a trimer of dimers6 (Suppl. Fig. 2a, b). This hexameric structure is a prerequisite for proper UGDH enzymatic
function15. The 23 germline mutations presented in this study are
distributed throughout the UGDH gene and its encoded protein
(Fig. 2a). One of the variants in Family 12 mutates the ﬁrst
nucleotide of exon 8 (c.907 G > A; p.Val303Ile, Fig. 2a, b), which
is predicted to affect the splice donor site16. Three different
nonsense mutations were found in a compound heterozygous
state with a missense mutation (Fig. 2a and Suppl. Table 2). All
identiﬁed missense mutations are anticipated to be destabilizing
according to DUET17 (Suppl. Table 2, ΔΔG). The missense
mutations in residues Y14, I42 and A44, which are close to the
NAD-binding site (Fig. 2c and Suppl. Fig. 2c) are expected to
impair NAD+ reduction. Alteration of residues in the central
domain such as I255, G271, M306, and R317 are expected to
affect homo-dimerization18 (Fig. 2b and Suppl. Fig. 2d). The I116
residue (located in the NAD-binding domain), as well as the R393
and A410 residues (UDP-Glc binding domain) sit at the dimerdimer interface19 (Fig. 2d), suggesting that these variants may
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prevent UGDH from assembling into a functional hexameric
enzyme.
To better understand the effect of the mutations on UGDH, we
then derived and biobanked primary dermal ﬁbroblasts from
patients F3-II:1 (R393W/A410S), F4-II:1 (Y14C/S72P), F5-II:1
(A82T/A82T) and F6-II:1 (R65*/Y367C), and a non-affected
parent F5-I:1 (WT/A82T). Endogenous UGDH messenger RNA
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T2, A

T2, A
8 months old
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Flair, A

T1, S

*

(mRNA) levels were not signiﬁcantly different in patients’
primary cells as compared to control ﬁbroblasts (Fig. 3a, top
panels). In contrast, we observed signiﬁcant changes in
endogenous UGDH protein levels for three of the four alleles
studied. Fibroblasts with compound heterozygous R393W/A410S
mutations displayed comparable UGDH levels relative to
wild-type (WT) cells, while patients’ cells with R65*/Y367C,
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Fig. 1 Clinical and genetic ﬁndings in 21 affected individuals diagnosed with Jamuar Syndrome consisting of developmental epileptic encephalopathy.
a Pedigrees of 19 families segregating autosomal recessive developmental epileptic encephalopathy. Countries of origin are speciﬁed above each pedigree.
Filled black symbols, affected individuals. Crossed symbols, deceased individual. Mutations in UGDH protein are presented below pedigrees. Homozygous
mutations are presented in bold (m in the pedigrees). Compound heterozygous mutations are presented according to the parental origin of the mutation
with a maternal origin in the ﬁrst row (m1 in the pedigrees), and a paternal, de novo or unknown origin in the second row (m2 in the pedigrees). Healthy
siblings that could be sequenced are heterozygous [F6-II:2 (p.Arg65*), F11-II:2 (p.Ala44Val), and F18-II:3 (p.Arg317Gln)]. b Facial photographs of 14
affected individuals with mild craniofacial dysmorphisms, including short and ﬂattened philtrum, protruding earlobes, ptosis blepharophimosis, and
epicanthic folds. c Spectrum of MRI ﬁndings in exemplary patients showing no evidence for maldevelopment but displaying variable abnormalities ranging
from abnormal myelination and/or cerebral or cerebellar atrophy, to normal ﬁndings. Patient F5-II:2 presented with a normal MRI, including normal
myelination at 2 years of age. In contrast, MRI of patient F3-II:1 revealed some myelination of cerebellar peduncles at 5 months (arrow) and no progress of
myelination on follow-up at 15 months, indicative of hypomyelination. In addition, repeated MRI revealed enlarged posterior ventricles over time (arrow
heads). MRI of patient F6-II:1 at 7 days of age also proved normal, the circle indicates onset of myelination in the Posterior Limb of the Internal Capsule
(PLIC) according to age. Patient F7-II:1 showed mild cerebellar atrophy at 4 years of age. Patient F9-II:1 showed slightly delayed myelination on axial T2 and
cerebellar atrophy on coronal and sagittal T1 images (stars). Patient F14-II:1 showed a diffuse cerebral atrophy, ventriculomegaly, thin corpus callosum,
vermian, and lobar cerebellar atrophy, with normal brainstem, hyperintensity of cerebellar cortex in T2-weighted images (white square). Patient F15-II:1
presented with normal MRI at 5 months, but with severe diffuse atrophy, bilateral symmetrical hyperintensities of thalami and globus pallidus (white
square) at 8 months old. In all pictures, MRI pulse sequences (T1, T2, and Flair) and image orientation (S: sagittal, A: axial and C: coronal) are indicated in
the upper left corner.

Y14C/S72P, or homozygous A82T mutations showed dramatically reduced endogenous UGDH levels (Fig. 3a, bottom panels).
In contrast to the three nonsense mutations and the missense
mutation potentially affecting splicing, which are likely to cause
nonsense-mediated decay of the endogenous UGDH transcript,
the missense mutations are most likely impacting the stability of
the enzyme and/or its oxidoreductase activity. Consistently, we
observed a signiﬁcant decrease in the UGDH-catalyzed reduction
of NAD+ to NADH in patients’ primary ﬁbroblasts (R393W/
A410S, Y14C/S72P, or homozygous A82T mutations) while the
non-affected parent’s cells heterozygous for the A82T mutation
showed intermediate level of NAD+ reduction (Fig. 3b, left
panels). Patient’s cells with the homozygous A82T mutation also
exhibited a reduction in the synthesis of hyaluronic acid (HA),
which requires UDP-glucuronate, a product of UGDH enzymatic
activity (Fig. 3b, right panel). When produced in bacteria, mutant
UGDH had altered stability, kinetic, and biochemical properties
as compared to WT-UGDH. Compared to the wild-type enzyme,
mutant A44V and A82T UGDH (mutations found at the
homozygous state in the patients from Families 1 and 5,
respectively) were more susceptible to partial proteolysis by
trypsin (Fig. 3c). The stability of UGDHA44V could be partially
rescued upon incubation with substrate, product, or cofactor,
while the UGDHA82T remained strongly sensitive to proteolysis
regardless of the presence of any cofactor or substrate (Fig. 3c). A
thermal stability study showed that the melting temperature of
UGDHA44V was signiﬁcantly reduced relative to WT and could
only partially be rescued upon addition of substrate, product,
reduced or oxidized cofactor, or any combination thereof
(Fig. 3d). Notably, UGDHA82T was so intrinsically unstable that
a melting temperature was unable to be ascertained. By gel
ﬁltration chromatography, we investigated the effect of the A44V
and A82T mutations on UGDH oligomerization. When compared to UGDHWT, UGDHΔ132 (an obligate hexamer15), and
UGDHT325D (an obligate dimer15), we observed that UGDHA44V
and UGDHA82T proteins were mainly eluted as dimer and
monomer species, respectively, with virtually no stable hexameric
population (Fig. 3e). This suggests that the A44V and A82T
mutations may affect UGDH function by altering its capacity to
form active hexamers. Finally, using equal amounts of recombinant enzyme, we determined that UGDHA44V and UGDHA82T
were respectively 75 and 50% less efﬁcient at reducing NAD+ to
NADH as compared to UGDHWT (Fig. 3f). Similarly, comparison
of the steady state Michaelis–Menten kinetic constants (summarized in Table 2) showed that UGDHA44V Vmax was only ~ 50% of
the value of UGDHWT for both cofactor and substrate. In
4

contrast, Km was not signiﬁcantly different from UGDHWT for
either cofactor or substrate, revealing that the mutation results in
a reduced ability of the enzyme to catalyze the reaction, while still
being able to associate with NAD+ and UDP-Glc. Taken together,
our biochemical ﬁndings indicate that these missense mutations
mainly impact the enzymatic function of UGDH by altering its
quaternary structure and/or directly impairing its oxidoreductive
activity.
Patient-derived cerebral organoids partially phenocopy human
disease. Our attempts to model this developmental epileptic
encephalopathy using the existing zebraﬁsh hypomorphic lossof-function ugdh (c.992 T > A; p.I331D) allele known as jekyll
m15120–22 were unsuccessful (Suppl. Fig. 3). The behavioral
activity of homozygous jekyll mutant larvae were recorded in
presence or absence of the seizure-inducing drug pentylenetetrazol (PTZ)23. By quantitative PCR (qPCR), c-fos expression,
which marks neural activity23,24, similarly increased in a dosedependent manner upon PTZ treatment in all larvae regardless
of genotypes (Suppl. Fig. 3a–d). Homozygous mutant larvae did
not show signs of increased c-fos expression at basal state,
suggesting that ﬁsh depleted of Ugdh activity do not exhibit
spontaneous seizure and are equally responsive to PTZ treatment. As noted by reviewers, ugdh mutant ﬁsh do not have
fully-inﬂated swim bladders, which may contribute to their
reduced locomotor activity and demise before 14-dpf (Suppl.
Fig. 3e). These in vivo experiments suggest that zygotic ugdh
depletion in zebraﬁsh does not satisfactorily model the human
disease.
UGDH has been extensively studied in vertebrate model
organisms where its complete knockout causes embryonic
lethality around gastrulation25,26. To address its role in the
context of central nervous system (CNS) development in humans,
we attempted instead to model this disease in vitro by developing
cerebral organoids27,28 from several patients with compound
heterozygous R65*/Y367C, Y14C/S72P or homozygous A82T
mutations, and from a non-affected parent (WT/A82T). After
10 weeks of differentiation, the volume of cerebral organoids
from patients with biallelic UGDH mutations was on average 50%
smaller and showed rougher edges than that of WT or carrier
WT/A82T cerebral organoids (Fig. 4a, b and Suppl. Fig. 4a).
Quantitative reverse transcription PCR (RT-qPCR) analysis
revealed decreased levels of the early and intermediate neuronal
progenitors markers PAX6 and TBR2, respectively, while the
levels of neuronal marker TUJ1 were unchanged (Fig. 4c and
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Table 1 Simpliﬁed clinical ﬁndings and course of disease in patients with UGDH mutations from families F1 to F10.
Family

Patient

F1

II:4

Gender,
age at last
follow-up
F, 13 yrs

Main
phenotype

Age at
seizure onset

Epilepsy,
seizure types

Drug
sensitivity

IDEE

9 mths

Epileptic spasms

Resistant

F1

II:6

M, 5 yrs

IDEE

15 mths

Epileptic spasms

Resistant

Absence

Severe

Absence

F1

II:7

M, 4 yrs

IDEE

6 mths

Epileptic spasms

Resistant

Absence

Severe

Absence

F2

II:1

F, 23 mths

IDEE

5 mths

Resistant

Absence

Severe

ND

F3

II:1

M, 6 yrsa

IDEE

8 wks

Resistant

Absence

Severe

Absence

Yes, g-tube

Yes

F3
F4
F5

II:2
II:1
II:1

M, 2 yrs
M, 5 yrs
F, 14 years

IDEE
IDEE
ID, MD

4 mths
4 mths
3 yrs

Epileptic spasms
reported back
arching directyl
after birth
Epilepsy with focal
seizures, myoclonic
jerks, epileptic
spasms, status
epilepticus
Epileptic spasms
Epileptic spasms
Seizures in the
setting of fever

Swallowing/
feeding
difﬁculties
Yes,
open mouth
Yes, open
mouth drooling
Yes, open
mouth drooling
ND

Resistant
ND
Seizure-free on
sodium
valproate

Absence
Absence
Sitting at 12
mths, walking
at 3 yrs

Severe
Severe
Moderate

Yes, g-tube
Yes, g-tube
Yes

Yes
Yes
Yes

F5

II:2

F, 6 yrs

ID, MD

3 yrs

Infrequent seizures
in the setting
of fever

Seizure-free on
sodium
valproate

Sitting
unsupported at
23 mths, walking
at 3 yrs

Moderate

Yes

Yes

F6
F7

II:1
II:1

M, 4 mthsa
M, 7 yrs

NDEE
IDEE

First day of life
14 mths

ND
Resistant

ND
Sitting with
support at
14 mths

Severe
Severe

Yes
Yes, drooling,
g-tube

Yes
Yes

F8

II:1

F, 25 mths

IDEE

12 mths

Severe

Absence

Yes, g-tube

Yes

II:1

F, 4 yrs

IDEE

8 wks

Good response
to
ketogenic diet
ND

Absence

F9

Absence

Severe

Absence

Yes

Yes

F10

II:1

F, 5 mthsa

4 mths

Resistant

Absence

Severe

Absence

Yes, g-tube

Yes

F11

II:1

M, 16 mths

IDEE,
multiple
congenital
anomaliesb
IDEE

Epileptic spasms
Epileptic spasms,
gelastic seizures,
and other complex
partial seizures
Epileptic spasms,
stimulus-sensitive
startles
Epileptic spasms,
myoclonic seizures,
tonic seizures, clonic
seizures
Epileptic spasms

Absence
Absence
Slow
acquisition,
only single
words at 14
yrs
First words at
18 mths,
simple
phrases
at 6 yrs
ND
Absence

ND

Absence

Severe

Absence

Yes, NJ fed

Yes

F12

IV:3

F, 8 mths

NDEE

First day of life

ND

ND

Severe

ND

Yes, g-tube

Yes

F13

II:4

F, 13 mths

IDEE

2 mths

Resistant

Absence

Severe

ND

Yes, g-tube

Yes

F14

II:1

F, 8 yrs

IDEE

4 mths

Resistant

Absence

Severe

Absence

Yes, g-tube

Yes

F15
F16

II:1
II:1

F, 8 mths
F, 11 yrs

IDEE
IDEE

4 mths
12 mths

Resistant
Resistant

Absence
Absence

Severe
Severe

Absence
Absence

Yes
Yes, g-tube

Yes
Yes

F17
F18

II:2
II:1

F, 5 yrs
F, 8 yrs

ID, MD
IDEE

None
20 mths

n/a
Resistant

Absence
Absence

Severe
Severe

Absence
Absence

No
No

Yes
Yes

F19

II:1

F, 5 yrs

IDEE

30 mths

ND

Absence

Severe

Absence

No

Yes

F19

II:2

F, 3 yrs

IDEE

18 mths

ND

Absence

Severe

Absence

ND

Yes

F20

II:2

M, 6 yrs

IDEE

3 yrs

Epileptic spasm,
myoclonic seizure,
tonic seizure, atonic
seizure, clonic
seizures
Postpartum
jitteryness,
myoclonic jerks, and
epileptic spasms
Clusters of
epileptic spasms
Segmental and
synchronous
myoclonus, epileptic
spasms in ﬂexion
Epileptic spasms
Daily generalized
tonic and myoclonic
seizures
No epilepsy
Daily generalized
tonic clonic and
later myoclonic
seizures with eye
ﬂuttering
Recurrent
generalized tonic
clonic convulsions
Daily myoclonic
seizures with eye
ﬂuttering
Epileptic spasms,
myoclonic seizure,
and tonic seizure
Myoclonic seizure

ND

Absence

Severe

Absence

Yes with
difﬁculty

Yes

ND

Absence

Severe

Absence

Resistant
ND

Absence
ND

Severe
Severe

Absence
Delay

Yes with
difﬁculty
Yes, NJ fed
ND

Yes

Epileptic spasms
Seizures in the
setting of fever
Myoclonic seizures,
generalized tonic
clonic seizures
Myoclonic seizures,
generalized tonic
clonic seizures

Resistant

Absence

Severe

Absence

Yes, g-tube

Yes

Resistant

Absence

Severe

Absence

Yes, g-tube

Yes

3 mths

F21

II:2

F, 4 yrs

IDEE

18 mths

F22
F23

II:5
II:5

F, 9 yrs
F, 7 yrs

IDEE
IDEE

20 mths
5 mths

F24

II:1

M, 7 yrs

IDEE

6 mths

F25

II:4

M, 8 yrs

IDEE

11 mths

Motor
development at
last follow-up
Absence

Intellectual
disability

Speech

Severe

Absence

Hypotonia

Yes
Yes
Yes
Yes

ND
Mild

M male, F female, IDEE infantile developmental epileptic encephalopathy, NDEE neonatal onset developmental epileptic encephalopathy, MD motor disorder, n/a not applicable, ND non-determined, ID
intellectual disability, g-tube gastrostomy tube, NJ nasojejunal, wks weeks, mths months, yrs years.
aAge at death.
bMultiple congenital

anomalies in F16-II:1: prenatal polyhydramnios; multiple ocular anomalies (bilateral cataracts, multiple bilateral lens colobomas, bilateral microphthalmia, hypoplastic iris, iris and
lenticular vascularization, bilateral anterior segment dysgenesis, posterior synechiae bilaterally secondary to neovascularization); megacystis; neurogenic bladder; moderate hiatal hernia; camptodactyly
of 3rd and 4th ﬁngers and overriding 2nd and 4th digits on the right hand; long tapered ﬁngers; skeletal survey showed overlapping of the parietal bones and mild elongation of the 2nd through 5th
ﬁngers.
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Fig. 2 Mutations in UGDH enzyme possibly affect critical amino-acids. a UGDH genomic and protein domain structures. Type and positions of 22
germline UGDH mutations. 5′ and 3′ UTRs are shown in dark gray. NAD-binding (blue), central (pink), and UDP-binding (orange) domains are highlighted.
Homozygous mutations are shown in bold. Compound heterozygous mutations that are in trans are linked by a line below the UGDH domain structure.
b–d Three close-up views ribbon diagrams of the UGDH protein bound to UDP-Glc and NADH. b Interface between the central domains of subunits A and
B. c NAD-binding site in NAD-binding domain of subunit A. Distances between NADH and mutated residues in patients are measured in Angström (Å).
d Interface between the subunit A NAD-binding domain with the subunit C UDP-Glc-binding domain. In all the structures, residues carrying missense
mutations in the patients are highlighted as 3D backbone. Residues Q110 and T325 known to interact together for dimer formation15; and residue V132,
which is important for hexamerization15 are highlighted in black backbone. In all the structures, NAD-binding (blue), central (light/dark pink), and UDPbinding (orange) domains are shown. UDP-Glc (dark red) and NADH (midnight blue) are represented as colored carbon backbones. Adapted from PDB
code 2Q3E6 using the Swiss-Pdb Viewer software67. For gels and graphs source data, please refer to the source data ﬁles 1 and 2.
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Suppl. Fig. 4b). Immunoﬂuorescence revealed similar amounts of
peripheral neurons marked by TUJ1, and astrocytes marked by
GFAP while ventricular zones marked by SOX2-positive neuronal
progenitors were appreciably less proliferative. This was
evidenced by reduced PCNA staining in mutant cerebral
organoids relative to WT and WT/A82T sections (Fig. 4d and
Suppl. Fig. 4c). These results argue that reduced UGDH activity is
associated with impaired neuronal development in vitro, causing
atrophy of patient-derived cerebral organoids. Even though our
cerebral organoid data is congruent with our patients’ phenotype
and biochemistry data, replicative studies with additional WT and
complete UGDH knockout lines are warranted in light of the

known variability in induced pluripotent stem cells (iPSCs’)
response to differentiation protocols.
To understand whether mutations in UGDH directly affect
neuronal function, we also differentiated WT, non-affected parent
(WT/A82T), and patient (Y14C/S72P) iPSCs into neuroprecursor cells (NPCs), which were subsequently matured into
neurons over a period of 21 days. Using a multi-electrode array
(MEA) system, and in contrast to neurons mutant for
CAMK2A29, no signiﬁcant differences between controls and
mutant UGDH neurons were recorded for either the total number
of spontaneous spikes or the mean ﬁring rate (Suppl. Fig. 4d).
Altogether, these in vitro experiments suggest that while UGDH
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Fig. 3 Biallelic UGDH mutations behave as hypomorphic alleles. a RT-qPCR (top), western blotting (bottom), and b enzymatic activity, assessed by
measuring NADH production (left panel) and quantiﬁcation of HA (right panel), for endogenous UGDH using patient-derived primary ﬁbroblasts. a, b
Control (WT/WT), unaffected mother F5-I:1 (WT/A82T) and 4 (in a) or 3 (in b) different patients’ ﬁbroblasts (F5-II:1: A82T/A82T, F3-II:1: R393W/
A410S, F4-II:1: Y14C/S72P, and F6-II:1: R65*/Y367C). a (top) Endogenous UGDH mRNA levels are normalized to β-ACTIN and GAPDH. Fold change relative
to control (WT/WT) is plotted. a (bottom) Western blot analysis for endogenous UGDH protein using cellular extracts. GAPDH is used as a loading
control. b (left) UGDH enzymatic activity measured as the conversion of NAD+ to NADH in whole-cell lysates. b (right) UGDH enzymatic activity
measured as the HA production in conditioned media from primary ﬁbroblast cultures. c Western blot analysis for UGDH sensitivity to limited proteolysis
using puriﬁed WT and mutant (A44V and A82T) UGDH proteins in the absence or presence of its substrates and/or cofactors, as indicated. Results are
representative of at least three experimental replicates. d Puriﬁed UGDH WT and A44V melting temperature (Tm) in the absence or presence of its
substrates and/or cofactors, as indicated. Mean of three experiments ± S.D. is plotted for the Tm of each enzyme. e Representative traces at λ = 280 nm of
puriﬁed WT and mutant UGDH proteins fractionated by size exclusion chromatography. WT, obligate dimer Δ13215, obligate hexamer T325D15, A44V and
A82T UGDH are plotted in the graph. Dashed lines correspond to the known hexamer, dimer and monomer peak elution times. f Puriﬁed WT, A44V, and
A82T UGDH enzymatic activity measured as the conversion of NAD + to NADH. Asterisks indicate p-values of p < 0.05(*), p < 0.01(**), and p < 0.001
(***), NS: non-signiﬁcant (p > 0.05) as determined by Student t-test. For gels and graphs source data, please refer to the source data ﬁles 1 and 2.

Table 2 Summary of WT and mutant UGDH kinetic
constants.

UDP-glucose
WT
A44V
A82T
NAD+
WT
A44V
A82T

Km (µM)

Vmax (nmol/min/mg)

28.6 ± 6.8
15.9 ± 2.3*
ND

235.6 ± 12.5
118.3 ± 3.3***
ND

401 ± 75
316 ± 54 NS
ND

219.2 ± 11.2
109.4 ± 4.5***
ND

Steady state rate constants for UGDHWT and UGDHA44V were determined by varying UDPglucose or NAD+ independently and ﬁtting to the Michaelis–Menten equation. UGDHA82T
steady state constants could not be determined. Values indicate mean ± SD of triplicate assays.
Asterisks indicate p-values of p < 0.05(*) and p < 0.001(***), NS: non-signiﬁcant (p > 0.05) as
determined by Student t-test. ND: not determined.

is not required for proper function of isolated neurons in culture,
its absence signiﬁcantly affects neuronal differentiation in
cerebral organoids, which may provide a powerful platform to
study the pathogenesis for the new disease in vitro.
Discussion
In this study, we described disease-causing mutations in UGDH
in humans. These 23 coding variants represent an allelic series of
germline mutations, which when inherited recessively are
responsible for epileptic encephalopathy with variable degrees of
developmental delay. We propose to name this novel Mendelian
disease Jamuar Syndrome, a member of the early infantile epileptic encephalopathies (EIEE). The genetic, biochemical, cellular
and developmental ﬁndings reveal that these UGDH germline
mutations behave as loss-of-function alleles. This was conﬁrmed
in vitro using patient-derived cerebral organoids, which showed
marked underdevelopment. In zebraﬁsh, we found that hypomorphic ugdhI331D/I331D mutant larvae did not show signs of
increased seizures at baseline or after PTZ treatment. The brainspeciﬁc UGDH phenotype in humans may come as a surprise
since in Drosophila, zebraﬁsh, and mouse, complete knockout of
Ugdh cause early and lethal gastrulation defects by hindering FGF
signaling25,30–32. One potential explanation for this incongruity is
that other proteoglycans not reliant on UGDH activity for the
synthesis of UDP-GlcA or UDP-Xylose (UDP-Xyl) may be solicited and help bypass the need for UGDH during human gastrulation. Alternatively, a complete knockout of UGDH in
humans may not be viable as we did not identify any homozygous
or compound heterozygous truncating mutations. A search in
ExAC for homozygous variants resulted in mostly synonymous or
8

non-coding variants. Only two homozygous missense variants
were detected, but no homozygous truncating mutations were
seen (Suppl. Table 3). This suggests that the severity of the epileptic encephalopathy may correlate with the amount of residual
UGDH activity, the extent of which may be sufﬁcient to allow
gastrulation to take place during early human embryonic stages
but may be limiting for neuronal development thereafter.
As UDP-GlcA is the major product of the UGDH enzyme, it is
possible that reduced levels of UDP-GlcA may trigger a cascade of
secondary pathogenic events resulting in neurodevelopmental
delay and encephalopathy. In support of this, is the recent
demonstration that a homozygous loss-of-function mutation in
the upstream enzyme UGP2 is also responsible for a severe form
of developmental epileptic encephalopathy in humans33. UDPGlcA is not only needed for detoxiﬁcation via glucuronidation,
but is also a key component of glycosaminoglycans (GAGs).
UGDH deﬁciency might parralel other neurological diseases with
defects in GAG synthesis, modiﬁcation, and degradation. For
example, EXTL3 and CHSY1 mutations, which affect heparan
sulfate and chondroitin sulfate synthesis, respectively, cause
developmental delay and intellectual disabilities34,35. Defects in
heparan sulfate modiﬁcation caused by NDST1 mutations are
responsible for intellectual disability associated with epilepsy36.
Moreover, mucopolysaccaridoses, diseases caused by defects in
GAG degradation, affect cognitive development37. In addition,
proteoglycans containing GlcA derived from UDP-GlcA are
major components of the extracellular matrix (ECM) and key
players in neuronal development and plasticity38, particularly in
areas important for neuronal migration39. In human, various
psychiatric and intellectual disorders are caused by mutations in
genes involved in ECM homeostasis and may be driven by neuronal migration defects38. The central role of UDP-GlcA may
open a window for early therapeutic interventions. In plants and
lower animals, including zebraﬁsh, UDP-GlcA can be synthesized
by two alternative pathways. Apart from UGDH, UDP-GlcA can
be generated via the myo-inositol oxygenation pathway from
glucuronic acid by glucuronokinase and UDP-glucuronic acid
pyrophosphorylase40. If a similar route exists in humans, supplementation of glucuronate may help to enhance this alternative
pathway and increase levels of UDP-GlcA levels and its essential
metabolites. To this date, however, the existence of human
homologs of glucuronokinase and UDP-glucuronic acid pyrophosphorylase remains to be proven.
Conservative estimates of disease frequency resulting from
germline UGDH mutations projects a prevalence of 1:14,000,000
to 1:2,000,000 (Suppl. Note 1). Considering that developmental
epileptic encephalopathies are most commonly caused by de novo
dominant mutations, this estimated prevalence seems relatively
frequent.
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Methods
Ethical approval. Written informed consent was obtained from the parents of the
underage patients for diagnostic procedures and next-generation sequencing, as
well as for the publication of identifying facial images in Fig. 1b. The study has been
approved by the local Institutional Review Board of the Medical Faculty of the
University of Tübingen, Germany (vote 180/2010BO1).

Exome sequencing. To unravel the molecular cause of the disease exome
sequencing were performed at different genetic institutes using next-generation
sequencing techniques according to local standard protocols. Variants were

conﬁrmed via Sanger sequencing using standard methods and chemicals (primer
sequences are available on request).
Family 1: Exome sequencing for two affected siblings was performed on a
HiSeq2500 System (Illumina, CA) after enrichment with SureSelectXT Human All
Exon V5 (Agilent, Santa Clara CA). FASTQ ﬁles were imported into GENESIS
(http://thegenesisprojectfoundation.org/)12 for further analysis using a pipeline
build on BWA41, Picard, and FreeBayes. Variants were ﬁltered for changes that
segregated in an autosomal recessive fashion and passed the following ﬁlter criteria:
(i) frequency in public databases (ExAC10 minor allele frequency (MAF) <0.1%),
(ii) present in <5 families within GENESIS ( ∼ 4,300 exomes), (iii) conserved
(PhyloP 100-way score >2 or PhastCons (100 vertebrate genomes) >0.75), (iv)
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Fig. 4 Patient-derived cerebral organoids are underdeveloped. a Volumes (mean ± SD) and b representative images (scale bar = 1 mm) of cerebral
organoids derived from iPSCs from WT (n = 18 organoids from the same batch), unaffected parent (UGDH WT/A82T, n = 15), and patients (UGDH A82T/
A82T (n = 10), Y14C/S72P (n = 7), and R65*/Y367C (n = 6) after 10 weeks of differentiation. Lower right panel: close-up views of the edges of indicated
cerebral organoids. Scale bar = 500 μm. c RT-qPCR for neuronal differentiation markers (PAX6, TBR2, and TUJ1) in WT (n = 4 cerebral organoids),
unaffected parent (WT/A82T, n = 3), and patients (A82T/A82T, Y14C/S72P, and R65*/Y367C, n = 3 each) cerebral organoids. Levels of expression are
normalized to GAPDH. Mean ± SD fold change relative to WT is plotted. d Representative images of consecutive sections of cerebral organoids derived
from iPSCs from WT (N = 5 cerebral organoids, n = 40 ventricle-like zones), unaffected parent (WT/A82T, N = 4, n = 15), and patients (A82T/A82T N =
3, n = 40, Y14C/S72P N = 4, n = 18, and R65*/Y367C N = 2, n = 9) stained with H&E, and immunostained with markers TUJ1/PCNA/DAPI, SOX2/DAPI,
and GFAP/DAPI. Scale bar = 100 μm. a, c Asterisks indicate p-values of p < 0.05(*), p < 0.001(***), NS: non-signiﬁcant (p > 0.05) as determined by
ANOVA test with Bonferroni correction. a–c Cerebral organoids represented here are all from batch 2 and derived from iPSCs clone 1 for each genotype,
see Suppl. Fig. 4 for more information. For graphs source data, please refer to the source data ﬁle 2.

CADD score >12, and (v) sufﬁcient quality scores (Genotype Quality >75). In
addition, variants had to be present in exomes from both siblings. This resulted in a
list of seven variants (Suppl. Table 1), out of which only the homozygous missense
variant c.131 C > T in the UGDH gene segregated with the third affected sibling.
Families 2, 9, 10: Using genomic DNA from the proband and parents, the
exonic regions and ﬂanking splice junctions of the genome were captured using the
Agilent SureSelect Human All Exon V4 (50 Mb) or the Clinical Research Exome kit
(Agilent Technologies, Santa Clara, CA). Massively parallel (NextGen) sequencing
was done on an Illumina system with 100 bp or greater paired-end reads. Reads
were aligned to human genome build GRCh37/UCSC hg19, and analyzed for
sequence variants using a custom-developed analysis tool. Additional sequencing
technology and variant interpretation protocol has been previously described42.
The general assertion criteria for variant classiﬁcation are publicly available on the
GeneDx ClinVar submission page (http://www.ncbi.nlm.nih.gov/clinvar/
submitters/26957/). After variant stratiﬁcation based on population frequencies
within an internal database and ExAC10, inheritance, in silico predictors such as
Provean, Mutation Taster and CADD, GeneDX reported only the UGDH variants
to be the best potentially pathogenic candidates and connected to this project via
GeneMatcher entries.
Family 3: Samples of the oldest sibling and both parents were sequenced in
context of the EUROCORES project EuroEPINOMICS-RES, for which the
technical details have been reported before43. Brieﬂy, the trio underwent exome
sequencing at the Wellcome Trust Sanger Institute (Hinxton/Cambridge, UK).
Capturing of the exome was performed using the SureSelect Human All Exon
50 Mb exome kit (Agilent). The enriched exome libraries were then sequenced on a
HiSeq2000 platform (Illumina) as 75 bp paired-end reads. BWA was used to align
the sequenced reads to the reference genome (hg19). De novo analysis of these data
did not reveal any variants. As the younger sib later developed a similar disorder,
exome sequencing was also performed locally on the second sibling: for library
preparation, genomic DNA was sheared to the average size 150 bp (Covaris) and
the genome libraries prepared using KAPA HTP Lib Prep Kit Illumina 96 rxns
(07138008001). Exome capturing was performed using the SeqCap EZ Human
Exome v3.0 capture system and the sample was sequenced on the NextSeq500
platform using NextSeq500 High-output V2 kit. Mapping to the human reference
genome (Hg19) and variant calling were performed with the CLC Genomics
Workbench. Subsequent annotation and ﬁltering were executed with
GenomeComb44 (http://genomecomb.sourceforge.net/). Exome sequencing results
of the trio and the second sibling were merged and reannotated and the family was
reanalyzed as a quartet. Variants were ﬁltered based on following quality
parameters: coverage >7, quality >50 and not located in homopolymers >8 or
tandem repeats. Only variants present with a frequency <0.5% in control
population databases ExAC10 and Exome Variant Server, seen <3 times in the local
exome sequencing database, and with predicted impact on the encoded protein
(missense, nonsense, frameshift, deletions, insertions and (essential) splice site)
were retained for further analysis. Remaining variants were ﬁltered under an
autosomal recessive (homozygous or compound heterozygous) and x-linked
hypothesis. In addition, heterozygous variants called in both siblings and absent in
the parents were selected under a parental mosaics for which the ExAC10 ﬁlter was
set at <2 calls. This analysis revealed only this one compound heterozygous UGDH
variants.
Family 4: Parent-proband trio exomes were prepared using the SureSelect
Target Enrichment System (Agilent, Santa Clara CA) and sequenced on a
HiSeq2000 System (Illumina, CA). Data processing, bioinformatics pipeline (for
alignment, variant calling, annotation, and genetic model ﬁltering), and analyses
were previously described45. The compound heterozygous rare missense alterations
in the UGDH gene, c.214T > C and c.41A > G, were interpreted as the only
candidate genetic etiology.
Family 5: The exome library was prepared on an ION OneTouch System and
sequenced on an Ion Proton instrument (Life Technologies, Carlsbad, CA, USA)
using one ION PI chip. Sequence reads were aligned to the human GRCh37/hg19.
Variants were ﬁltered for common SNPs using the NCBI’s “common and no
known medical impacts” database (ClinVar), ExAC10, as well as an in-house
database of 406 sequenced samples. Additional ﬁlters were applied to retain
proband’s exonic variants that were homozygous while heterozygous in both
10

parents. Out of 5 homozygous variants, only one missense variant c.244G > A in
the UGDH gene was found to segregate with the disease.
Family 6: Exome sequencing was performed on a NextSeq 500 System
(Illumina, CA USA), with a 2 × 150 bp high-output sequencing kit after enrichment
with Seq Cap EZ MedExome kit (Roche, Basel Switzerland). Sequence alignment,
variant calling, and variant annotation was performed by Genosplice Technology
(Paris France) with BWA 0.7.12, picard-tools-1.121, GenomeAnalysisTK-2014.317-g0583018 and SNPEff-4.2 with additional annotations from ClinVar and
HGMD. The compound heterozygous UGDH variants were selected to be the most
promising candidates and were thus submitted to GeneMatcher.
Families 7, 8, 16–25: Exome sequencing was performed essentially as
described before46 for families 7, 8, and 16–25. Target regions were enriched
using the Agilent SureSelectXT Human All Exon 50 Mb Kit. Whole-exome
sequencing was performed on the Illumina HiSeq platform (BGI, Copenhagen,
Denmark) followed by data processing with BWA (read alignment,) and GATK
(variant calling) software packages. Variants were annotated using an in-house
developed pipeline. Prioritization of variants was done by an in-house designed
“variant interface” and manual curation. As four families with similar phenotype
shared the homozygous p.R317Q as best candidate, a GeneMatcher entry was
made and the in-house database was systematically screened for other
potentially pathogenic UGDH variants. This allowed the identiﬁcation of
families 18 to 25.
Family 11: The sequencing was performed at Claritas Genomics (Cambridge,
USA). Extracted genomic DNA was ampliﬁed using the AmpliSeq system and
sequenced using an IonTorrent Proton Instrument. Alignment and variant calling
of the nuclear DNA was done on Proton data using Torrent Suite 4.4 Software.
Nuclear variants were ﬁltered for quality using a custom ﬁltering tool. In addition,
extracted genomic and mitochondrial DNA was also run on an Agilent Clinical
Research Exome capture sequence and then sequenced using an Illumina NextSeq
instrument. Alignment and variant calling on NextSeq data was performed by an
implementation of GATK Best Practices Pipeline. Genomic DNA results from the
two NGS runs on the proband were combined and annotated by a custom
bioinformatics pipeline. Besides a heterozygous SLC6A5 missense variant inherited
from the unaffected father, the compound heterozygous UGDH variants were the
only candidates reported that had a minor allele frequency (MAF) of < or = 0.01%
that passed the laboratory’s quality metrics and were not de novo, X-linked or had
biallelic variants.
Family 12: Isolated genomic DNA from peripheral blood leukocytes of proband
and parents was captured with the Agilent Sure Select Clinical Research Exome
(CRE) kit (v2). Sequencing was carried out with 150 bp paired-end reads on the
Illumina HiSeq 4000. Reads alignments to the GRCh37/UCSC hg19 build were
achieved using BWA (BWA-MEM v0.7.13). Variants were called using GATK
(v3.7 (reference: http://www.broadinstitute.org/gatk/). Annotated Variants were
ﬁltered and prioritized using the Bench lab NGS v5.0.2 platform (Agilent
technologies). The full exome analysis revealed the compound heterozygous
variants in UGDH. The family was linked to this cohort via GeneMatcher.
Family 13: The exonic regions and ﬂanking splice junctions of the genome were
captured using proprietary GeneDx tools. Sequencing was performed on an
Illumina system with 100 bp or greater paired-end reads. Reads were aligned to the
human genome build GRCh37/UCSC hg19. A custom-developed analysis tool
(Xome Analyzer) was used to call sequence variants. Sanger sequencing was used to
conﬁrm all potentially pathogenic variants identiﬁed in available family members.
Additional variants not included in this report are available upon request.
Family 14: The patient F14-II:1 was enrolled in the ongoing “Undiagnosed
Patients Program” at the Ospedale Pediatrico Bambino Gesù, Rome. Targeted
enrichment (SureSelect All Exon V.4, Agilent) used genomic DNA extracted from
circulating leukocytes for the affected subject and both parents, and parallel
sequencing was performed using an Illumina HiSeq2000 platform, obtaining about
70 million reads. The data analysis was performed using an in-house implemented
pipeline, which mainly take advantage of the Genome Analysis Toolkit (GATK
V.3.7)47 framework, as previously reported48,49). The functional annotation of
variants was achieved using SnpEff and dbNSFP (V.3.0)50–52. The functional
impact of variants was analyzed by Combined Annotation Dependent Depletion
(CADD) V.1.3, M-CAP V.1.0, and InterVar V.0.1.6 algorithms11,53,54. Two
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compound heterozygous private missense variants in the UGDH gene, c.347T > C
and c.1328G > A, were interpreted as the only candidate genetic etiology.
Family 15: genomic DNA from of the proband and parents were enriched for
exonic sequences with the SureSelect Human All Exon 50 Mb V5 Kit (Agilent
Technologies, Santa Clara, California, USA). The HiSeq2500 (Illumina, San Diego,
California, USA) was used to generate 125-bp paired-end runs of sequences. Reads
were aligned and variant called with DNAnexus (Palo Alto, California, USA) using
the reference human genome assembly hg19 (GRCh37). A mean coverage of 104x
was achieved for the proband. Data analysis was preformed using an in-house
bioinformatics pipeline. The compound heterozygous UGDH variants were
selected to be the most promising candidates and were thus submitted to
GeneMatcher.
Brain magnetic resonance imaging. Magnetic resonance images (MRI) have been
recorded on 1.5 or 3 Tesla scanners at the different clinical sites. Sagittal, transversal, and coronal images of the brain have been acquired with standard
sequences, including T1, T2, and Flair images.
Cell culture. Primary dermal ﬁbroblast cultures were established from skin
biopsies obtained from individuals F3-II:1, F4-II:1, F5-I:1, and F5-II:1 according
to standard procedures55. In brief, primary ﬁbroblasts were derived from biopsy
samples and cultured in Dulbecco's modiﬁed Eagle medium (DMEM; HyClone,
SH30243.01) supplemented with 10% fetal bovine serum (Biological Industries)
and 2 mM L-glutamine (Biological Industries). Written informed consent of
healthy probands and parents of UGDH patients were received prior to biopsy
according to the ethical approvals of the local Institutional Review Boards (IRB).
Reverse transcription (RT-PCR) and quantitative PCR. Total RNAs were
extracted using the RNeasy Mini Kit (Qiagen). RNA (1 µg) was reverse transcribed
using the Iscript™ complementary DNA (cDNA) Synthesis Kit (Bio-Rad). Quantitative real-time PCRs were performed using Power SYBR green master mix
(Applied Biosystems) on the 7900HT Fast real-time PCR system (Applied Biosystems). qPCR primer sequences are as follows: UGDH (between exons 6 and 7) 5′
CTTGCCCAGAGAATAAGCAG3′ and 5′CAAATTCAGAACATCCTTTTGGA3′;
β-ACTIN 5′ATGTTTGAGACCTTCACACC3′ and 5′AGGTAGTCAGTCAGGT
CCCGGCC3′; GAPDH 5′TGAACCACCAACTGCTTAGC3′ and 5′GGCATGGAC
TGTGGTCATGAG3′.
Protein isolation and analysis. Cells were lysed using ice-cold RIPA buffer (250
mM Tris, pH: 7.5; 150 mM NaCl; 1% NP-40; 0.5% Na deoxycholate; protease
inhibitors P2714 [Sigma-Aldrich, USA]). The total protein concentration of cell
lysates was determined using the BCA Protein assay Kit (Thermo Fisher Scientiﬁc,
USA). Sixty micrograms of total proteins were reduced in Laemeli loading buffer,
denatured at 95 °C for 10 min, separated by 4–20% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (Invitrogen, Germany) electrophoresis
and transferred onto Immun-Blot® Low Fluorescence PVDF Membranes
(BIORAD). Protein detection was performed using anti-UGDH (1:500, SigmaAldrich, USA, HPA036657) and anti-GAPDH (1:2000, Santa Cruz Biotechnology
Inc., USA, SC 47724) antibodies. Secondary antibodies conjugated to peroxidase
(1:4000, Santa Cruz Biotechnology Inc., USA) were used and blots were developed
using an enhanced chemiluminescence system, Pierce™ ECL Plus (Thermo Scientiﬁc), followed by detection on autoradiographic ﬁlms.
HA quantiﬁcation. HA content was compared in the culture-conditioned media
from ﬁbroblasts expressing WT or mutant UGDH using a competitive binding
assay as previously described19. Fibroblasts were grown in 10 cm plates, 1 mL of
conditioned media was aspirated from technical replicates, and cells were counted.
HA concentration was interpolated from a standard curve, normalized to cell
number, and plotted as mean ± SD. Statistical signiﬁcance was assessed by Student’s t-test with at least three technical triplicates.
Speciﬁc activity measurement of UGDH. Fibroblasts expressing WT or mutant
UGDH were assayed for UGDH-speciﬁc activity essentially as previously described56. Fibroblasts were cultured in 15 cm plates, washed three times with cold 1x
PBS, and centrifuged at 1500 rpm for 5 min. Cells were resuspended in twice the
pellet volume of Lysis Buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM
EDTA, and protease inhibitor cocktail). Samples were transferred to tubes with an
equal volume of acid washed glass beads (Sigma) and lysed in the Bullet Blender 24
(Next Advance) at speed 8 for 3 min. The resulting supernatant was centrifuged at
13,000 rpm for 15 min to obtain ﬁnal lysates. Enzymatic activity of the lysates
(50 µg) was assayed with 1 mM UDP-glucose and 1 mM NAD+ in the presence or
absence of 1 mM UDP-xylose, a UGDH-speciﬁc inhibitor, and monitored for
changes in NADH, A340. Reaction rates for samples containing UDP-Xyl were
subtracted from samples without UDP-Xyl to obtain UGDH-speciﬁc activity
reported as [NADH] in nmol min−1 mg−1 lysate as described above. Each ﬁbroblast cell line analyzed contained three or more technical replicates for reactions
with and without UDP-Xyl plotted as mean ± SD. Statistical signiﬁcance was
assessed by one-way ANOVA (Prism).
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Generation and puriﬁcation of UGDH point mutants. Point mutants of human
UGDH were generated from the codon optimized E. coli expression construct,
WT-UGDH pET28a, using polymerase chain reaction mutagenesis with appropriate primers as previously described19,57. Sequences were veriﬁed by Euroﬁns
MWG Operon (Huntsville, AL). The UGDH mutant constructs were expressed in
E. coli strain BL21(DE3) grown in 2xYT medium containing 50 mg L−1 kanamycin
at 37 °C. At an OD600 of 0.6-0.8, protein expression was induced with the addition
of IPTG at a ﬁnal concentration of 0.5 mM, and cultures were incubated at 18 °C
overnight. Cells were harvested by centrifugation and lysed by sonication. All
UGDH point mutants were expressed in the soluble fraction, and enzymes were
puriﬁed by afﬁnity chromatography using a HisTrap FF column (GE Healthcare)
according to the manufacturer’s protocol. The average protein yields were: ~20 mg
L−1 for UGDH WT and T325D, ~1.5 mg L−1 for UGDH A82T, and ~6 mg/L for
UGDH A44V. Puriﬁed protein was dialyzed against 20 mM Tris-HCl pH 7.4
containing 1 mM dithiothreitol (DTT), concentrated, ﬂash frozen in liquid nitrogen, and stored at –80 °C.
Analytical gel ﬁltration. Puriﬁed recombinant UGDH WT and all point mutants
were analyzed by size exclusion chromatography as previously described57. All
samples were centrifuged prior to loading. Each apoprotein sample was injected
into a 250 µL loop and separated by FPLC in 1x PBS containing 1 mM DTT at a
ﬂow rate of 0.5 mL min−1 on a Superdex 300 10/200 GL gel ﬁltration column (GE
Healthcare). Elution was monitored by A280 and plotted to compare alterations in
oligomeric state.
Trypsin susceptibility assay. Puriﬁed recombinant WT-UGDH and all point
mutants were assessed by limited trypsin proteolysis as previously described19.
UGDH WT, A44V (10 µg), and A82T (14.2 µg) were digested with 10 ng trypsin in
1x PBS pH 7.4 for 2.5 h at room temperature in the absence or presence of 1 mM
UDP-glucose, 1 mM UDP-glucuronate, 5 mM NAD+, 5 mM NADH, or combinations that yielded abortive and productive ternary complexes. Samples were
analyzed by western blot probed for UGDH as previously described58.
Thermal stability measurement. Recombinant UGDH WT and A44V protein
were assessed for thermal stability as previously described19 with minor alterations.
All samples of UGDH WT and A44V (~15 µg) were incubated in 1x PBS and Sypro
Orange dye (Invitrogen; 1:500 dilution) in the absence or presence of 1 mM UDPglucose, 1 mM UDP-glucuronate, 5 mM NAD+, 5 mM NADH, or in combinations
that yielded abortive and productive ternary complexes. Samples were handled at
room temperature and transferred to an iCycler MyiQ thermocycler (Bio-Rad) for
incremental thermal denaturation. Tm was plotted as the mean ± SD for seven
replicates. Statistical signiﬁcance was assessed by two-way ANOVA (Prism).
Saturating enzymatic activity and kinetic characterization. Enzyme activity of
recombinant UGDH WT and all point mutants was characterized as described
previously57 with minor alterations. Enzymatic activity was calculated by NADH
turnover using the NADH extinction coefﬁcient of 6220 M−1 cm−1. UGDH A82T
activity was converted to [NADH] in nmol min−1 mg−1 UGDH and subsequently
normalized to the fractional purity of UGDH in the sample preparation. Samples
were run in triplicate and statistical signiﬁcance was determined using Student’s
t-test. Michaelis rate constants, Km and Vmax, were determined for UGDH WT
and A44V as previously described using a 96-well plate assay to measure the
change in NADH (A340) with respect to both the substrate, UDP-glucose, and
cofactor, NAD+.
iPSCs reprogramming. WT, WT/A82T, and A82T/A82T ﬁbroblasts were reprogrammed using the CytoTune™-iPS 2.0 Sendai Reprogramming Kit (Thermo Fisher
Scientiﬁc, A16517) in accordance with the manufacturer’s instructions. Brieﬂy,
ﬁbroblasts were transduced and plated after 7 days onto Matrigel Basement
Membrane Matrix (Corning, 354234) in mTeSR1 medium (STEMCELL Technologies, 85850). iPSC colonies were picked between days 17–28 and maintained in
Matrigel Basement Membrane Matrix and mTeSR1 for expansion. R393W/A410S,
R65*/Y367C, Y14C/S72P ﬁbroblasts were reprogrammed using the ReproRNA™OKSGM kit (Stemcell Technologies, 05930) in accordance with the manufacturer’s
instructions. Brieﬂy, ﬁbroblasts were plated onto Matrigel Basement Membrane
Matrix (Corning, 354234) and transfected with ReproRNA™-OKSGM cocktail.
Puromycin selection was carried out 1 day after transfection. iPSC colonies were
picked between 20 and 28 days after transfection and maintained in Matrigel
Basement Membrane Matrix and mTeSR1 for expansion. Between 1 and 3 clones
per genotype were maintained for further experiments.
Neuronal and cerebral organoid differentiation. Neuronal and cerebral organoid differentiation was performed as previously described27. Brieﬂy, on day 0 of
organoid culture, iPSCs were dissociated by accutase (STEMCELL Technologies,
07920) treatment to generate single cells. In total, 9000 cells were then plated per
well of an ultra-low-binding 96-well plate (Corning) in MEDI medium
[Knockout SR 20% (Thermo Fisher scientiﬁc, 10828-028), L-glutamine 2 mM
(Thermo Fisher scientiﬁc, 200 mM, 25030-081), Non-essential amino-acid
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(NEAA) 1 × (Thermo Fisher scientiﬁc, 100× , 11140-050), sodium pyruvate 1×
(Thermo Fisher scientiﬁc, 100 mM, 11360-070), and β-mercaptoethanol 1/1000
in neurobasal medium (Thermo Fisher scientiﬁc, A2477-501)] complemented
with 10 µM Rho-associated protein kinase (ROCK) inhibitor (STEMCELL
technology, Y-27632) and 0.05% polyvinyl alcohol. Embryoid bodies were fed
with this medium every other day for 6 days. Then, MEDI medium was replaced
with NIM-I medium [N2 1× (Thermo Fisher scientiﬁc, 100× , 17502-048), Lglutamine 2 mM, NEAA 1× , and heparin 1 µg mL−1 (Sigma-Aldrich, H3149) in
neurobasal medium] every other day for 6 additional days for the neuroepithelial
tissues induction. On day 11, tissues exhibiting neural ectoderm were transferred
to droplets of cold Matrigel (BD Biosciences) on a sheet of Paraﬁlm with dimples
in a low-adhesion 6-well plate (Corning). These droplets were allowed to gel
at 37 °C and were subsequently removed from the Paraﬁlm and grown in differentiation medium Dif-M [N2 0.5 × , B27 without vitamin A 1× (Thermo
Fisher scientiﬁc, 50 × , 12587-010), L-glutamine 2 mM, NEAA 1× , and βmercaptoethanol 1/1000 in neurobasal medium] for 4 days. On day 15, the
medium was replaced by Dif-M II medium [N2 0.5× , B27 1× (Thermo
Fisher scientiﬁc, 50× , 17504-001), L-glutamine 2 mM, NEAA 1× , and βmercaptoethanol 1/1000 in neurobasal medium], and the plates are placed on
a horizontal shaker rotating at 85 rpm. Cerebral organoids were grown up to
10 weeks with 75% of the medium changed weekly.
Histology and immunoﬂuorescence of organoids. Cerebral organoids were ﬁxed
in 4% paraformaldehyde (PFA) overnight at 4 °C, then washed in PBS for 10 min
and dehydrated by incubations in Ethanol (70%, 95% then 100%) for 1 h at 4 °C
followed by two times 1 h incubation with Xylene 100% at room temperature. The
cerebral organoids were then embedded in Paraplast Plus (Leica, 39602004) and
sectioned at 30 µm. Tissue sections were stained with Haematoxylin and Eosin
(H&E) or used for immunostaining. For immunoﬂuorescence, antigen retrieval was
performed by using the Antigen Retriever buffer (Citrate Buffer pH 6.0, Sigma, C
9999, 10× ). Sections were then blocked and permeabilized in blocking buffer (0.5%
Triton X-100 and 1% BSA in PBS) for 20 min. Sections were then incubated with
primary antibodies in blocking buffer at the following dilutions: SOX2 (mouse,
R&D systems, MAB2018, 1:200), TUJ1 (mouse, Biolegend MMS-435P, 1:3000),
GFAP (Rabbit, Dako Z0334, 1/2500), PCNA (Rabbit, abcam ab18197, 1 µg mL−1).
For visualization, an antibody anti-mouse immunoglobulin G (anti–mouse IgG)
Alexa Fluor 594 conjugate (Invitrogen, Molecular Probes) and an anti-rabbit IgG
Alexa Fluor 488 conjugate (Invitrogen, Molecular Probes) was applied. DNA was
stained by DAPI (1/500) and sections were mounted in ProLong Diamond Antifade mountant (Thermo Fisher Scientiﬁc, P36965). Images were collected by using
an Olympus FV3000 RS with a 20x objective.
RT and RT-qPCR. Total RNA of individual cerebral organoids was extracted using
the RNeasy Mini Kit (Qiagen, 74104). Total RNA (0.5 µg) was reverse transcribed
using the Iscript™ cDNA Synthesis Kit (Bio-Rad, 1708891). Real-time quantitative
PCRs were performed using the Power SYBR green master mix (Applied Biosystems, 4309155) on the 7900HT Fast real-time PCR system (Applied Biosystems).
qPCR primers were as previously described:59 PAX6 5′CCGTGTGCCTCAAC
CGTA3′ and 5′CACGGTTTACTGGGTCTGG3′; TBR2 5′AAATGGGTGACCT
GTGGCAAAGC3′ and 5′CTCCTGTCTCATCCAGTGGGAA3′; TUJ1 5′TCAG
CGTCTACTACAACGAGGC3′ and 5′GCCTGAAGAGATGTCCAAAGGC3′.
Neural induction. Neural induction was carried out by dual SMAD inhibition60.
iPSC were ﬁrst dissociated into single cells and seeded in low attachment 96-well ubottom plate at a density of 10,000 cells/well in Neural Induction Medium
[DMEM/F12 (Thermo Fisher Scientiﬁc, 10565-018) supplemented with B27
(Thermo Fisher Scientiﬁc, 17504044), N2 (Thermo Fisher Scientiﬁc, 17505048),
0.2 mM NEAA (Thermo Fisher Scientiﬁc, 11140-050), 100 nM LDN 193189
(STEMCELL Technologies, 72148), 10 µM SB431542 (STEMCELL Technologies,
72234) and 10 µM Y-27632 (STEMCELL Technologies, 72304)]. After 6 days, cells
were attached onto matrigel coated-plate in Neural Expansion Medium [DMEM/
F12 (Thermo Fisher Scientiﬁc, 10565-018) supplemented with B27 (Thermo Fisher
Scientiﬁc, 17504044), N2 (Thermo Fisher Scientiﬁc, 17505048), 0.2 mM NEAA
(Thermo Fisher Scientiﬁc, 11140-050) and 20 ng mL−1 βFGF (Stemgent, 03-0002)].
After 3–6 days, rosette structures were manually cut out and expanded as suspension culture in neural expansion medium.
Neuronal differentiation. iPSCs-derived Neuro-Precursor Cells (NPCs) were
differentiated into neurons for 21 days using a previously published protocol61
Brieﬂy, NPCs were plated at a density of 50,000 cells cm−2 in a poly-L-ornithine
and laminin-coated plates, cultured in N2B27 medium supplemented BDNF (20
ng mL−1), GDNF (20 ng mL−1), cAMP (N6,2′-O-dibutyryladenosine 3′,5′-cyclic
monophosphate; Sigma; 0.3 mM) and ascorbic acid (0.2 mM).
Multi-electrode Array (MEA) recordings. Neurons on day 21 were dissociated
and replated on 0.1 polyethylenimine (Sigma)-coated 48-well MEA plates (Axion
Biosystems) in BrainPhys media supplemented with BDNF, GDNF, cAMP, and
ascorbic acid as previously described62. Spontaneous neuronal activity was
12

observed and recorded at 37o C for 5 min every 2–3 days using the Maestro MEA
System (Axion Biosystem).
Zebraﬁsh strains and maintenance. All zebraﬁsh husbandry procedures were
performed in compliance with the Singapore National Advisory Committee on
Laboratory Animal Research Guidelines from the Institutional Animal Care and Use
Committee (IACUC, IACUC number 161172). The jek ugdhm151 mutant line63 was
used for this study and was maintained in the AB background. All embryos were
raised in egg water (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4).
Genomic DNA extraction. Genomic DNA from larvae used for the locomotion
assay was extracted by larval ﬁn clipping as previously described64. Brieﬂy,
microscopic caudal ﬁn slices of 3-dpf larvae were sectioned under a stereomicroscope. The ﬁns were then digested with proteinase K (Invitrogen, 25530049)
overnight at 65 °C, and the supernatant was used as a source of genomic DNA for
genotyping. In 7-dpf larvae, heads were used for c-fos qPCR analysis, while the rest
of the bodies was used for genotyping.
Genotyping of zebraﬁsh. Genotyping was performed via nested PCR to amplify
the exon 7 of ugdh, and restriction fragment length polymorphism as described
previously63. The ﬁrst PCR was performed with the following primers, 5′TGTATGTGCAGGTGATTGACA-3′ and 5′-TGTAGGTCACAGGTTTTTGACA3′. PCR products were cleaned-up by Exonuclease I (New England Biolabs,
M0293L) and FastAP Thermosensitive Alkaline Phosphatase (Thermo Fisher,
EF0651) treatment, and were then used as templates for a second PCR with the
following primers: 5′-GACATGAATGAATATCAGAGAAAGAG-3′ and 5′AGGAGAAACCCAACAACGC-3′. These PCR products were digested with the
MluI enzyme (New England Biolabs, R3198L) that only cuts when the mutation is
present.
c-fos qPCR experiments. 7-dpf larvae were ﬁrst incubated with increasing concentrations (up to 15 mM) of PTZ (Sigma, P6500) for 45 min and were then
decapitated. The bodies were used for genotyping and 20 larvae heads of the same
genotype were pooled together for total RNA extraction using the RNeasy Mini Kit
(Qiagen, 74104). Total RNA (0.5 µg) was reverse transcribed using the Iscript™
cDNA Synthesis Kit (Bio-Rad, 1708891). Real-time quantitative PCRs were performed using the Power SYBR green master mix (Applied Biosystems, 4309155) on
the 7900HT Fast real-time PCR system (Applied Biosystems). qPCR primers were
as follows: c-fos23 5′-AACTGTCACGGCGATCTCTT-3′ and 5′-GCAGGCATGTA
TGGTTCAGA-3′; gapdh 5′-GTGGAGTCTACTGGTGTCTT-3′ and 5′-GTGC
AGGAGGCATTGCTTAC-3′.
Twenty-four-well locomotion and convulsion test assay. A Basler Ace
(acA1300-200um; 1280 × 1024) camera was used to acquire videos of larval zebraﬁsh at 50 fps. A custom hardware setup was designed to acquire full frame videos
of 24-well ﬂat bottom plates using a 25 mm lens attachment to the camera placed
65 cm above the plate. The 24-well plates were backlit using a white light LED
lightbox that delivered uniform lighting across the entire ﬁeld. 7-dpf larval ﬁsh
were placed individually in each well in 500 µl of egg water and acclimated to the
setup for 10 min. Then, 500 µl of either egg water (negative control) or PTZ 30 mM
(15 mM ﬁnal concentration, Sigma, P6500) was added to the well. Three videos of
2 min each were acquired for a duration of 10 min for each condition tested. Fish
locomotion was tracked online during video recording on a custom written software in LabView (www.critta.org). Analysis of locomotion was automated and
performed blind ofﬂine after each experiment using custom written Python scripts
(available on Github: https://github.com/mechunderlyingbehavior/24-Well-LarvalLocomotion.git). In this assay, low and high speed were deﬁned as average speeds
of 0 to 8 mm/s and >8 mm s−1, respectively, based on a recent publication measuring convulsive-induced speed changes in zebraﬁsh larvae65.

Data availability
The data that support the ﬁndings of this study are available within the paper and its
supplementary information ﬁles. All identiﬁed variants have been deposited in the
ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/) under the name “UGDH001”.
Whole dataset from Family F3 was already published66 and deposited in the European
Genome-phenome Archive, accession numbers EGAS00001000190, EGAS00001000386,
and EGAS00001000048. Whole datasets from Families F5 and F15 are available upon
request from the corresponding authors. Consent restrictions preclude deposition of
sequencing data of the other families, however, speciﬁc information (e.g., secondary
variants etc., but not full datasets) can be obtained upon request from the corresponding
authors. Lists of primers and antibodies are in Supplementary Tables 4 and 5,
respectively. The source data underlying Fig. 3a–f, Fig. 4a, and c, Suppl. Fig. 3a–d, Suppl.
Fig. 4a, b, and d are provided as a Source Data ﬁle 1 (for gels) and 2 (for graphs).

Code availability
The custom written Python scripts used to track ﬁsh locomotion is available following
this link: https://github.com/mechunderlyingbehavior/24-Well-Larval-Locomotion.git.
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